Formycon is a leading and independent developer of high-quality biopharmaceutical biosimilars. With a focus on therapies in ophthalmology, immunology, and other important chronic diseases, they aim to provide better access to essential medications. They offer a wide range of services, from technical-pharmaceutical development to clinical studies and the preparation and submission of regulatory documents.

Their product portfolio includes innovative biosimilars that meet the highest quality standards. One notable project is FYB207, an antiviral medication based on a long-acting ACE2-IgG-Fc fusion molecule, developed specifically for the treatment of COVID-19. Formycon takes pride in their expertise as biosimilar developers and is committed to delivering effective and safe treatments.

Furthermore, Formycon is known for its diverse and inclusive corporate culture, fostering an environment of professionalism and teamwork. They offer excellent career opportunities in a dynamic and rapidly growing industry. Their commitment to diversity and mutual respect is the foundation of their success.

Stay informed about Formycon's latest news and developments through their news updates and newsletters. Formycon is dedicated to bringing high-quality biosimilars to patients worldwide